Matthias Pfisterer Drug-eluting stents and their additional benefit to low-risk patients were investigated in a cost-effectiveness analysis presented to the Stockholm cardiology meeting by Matthias Pf
Matthias Pfisterer
Drug-eluting stents and their additional benefit to low-risk patients were investigated in a cost-effectiveness analysis presented to the Stockholm cardiology meeting byMatthias Pfistererfrom Basel. Audio Medica talked with him.
Related Episodes
London School of Hygiene & Tropical Medicine Audio News – Undernutrirtion Causes a Third of Child Deaths
Zulfiqar Bhutta Reference: The Lancet, Maternal and Child Undernutrition Special Series With one child in three killed by it, childhood and maternal undernutrition are discussed in a special series of
Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes
Pierre Fenaux PIERRE FENAUX, Paris 13 University Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with
Large Risk Reduction For Rivaroxaban In Blood Clot Prevention
Bengt Eriksson REFERENCE: Abstract 6, American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta BENGT ERIKSSON, Gothenburg University In a large phase III trial of patients having a h